Xarelto

PreclinicalSmall molecule

Bayer

Xarelto is one of 9 small molecule programs targeting Thromboembolism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThromboembolismUnknown

ThromboembolismPreclinical

Unknown

Competition

Competitive Landscape

9 competitors in Thromboembolism

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

—2

Heparin Sodium

BBaxter Healthcare Corporation

Approved

1 3

Xylocaine

MMEDRx USA, Inc.

Approved

—4

Arixtra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Coumadin

Pradaxa

1 7

Coumadin

AAbbott

Preclinical

—8

Tissue Plasminogen Activator

NNeuroscience Trials Australia

Preclinical

1 9

Xarelto

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rivaroxaban4 trials

Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)

Completed·GGenuine Research Center, Egypt·Phase 1·NCT03071380·24 enrolled

Bioequivalence Study of Rivaroxaban 10 mg Film-coated Tablets

Completed·DDexa Medica Group·Phase 1·NCT06558058·28 enrolled

Bioequivalence Study of Rivaroxaban 20 mg Film-coated Tablets

Completed·DDexa Medica Group·Phase 1·NCT06558045·26 enrolled

Show 1 more trial

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions

Unknown status·PPharmtechnology LLC·Phase 1·NCT04729998·34 enrolled

Atrial Fibrillation3 trials

Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program

Completed·UUniversity Hospital, Montpellier·N/A·NCT02422602·196 enrolled

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

Completed· Bayer logo

Bayer·Phase 2·NCT00973245·102 enrolled

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

Completed· Bayer logo

Bayer·Phase 2·NCT00973323·100 enrolled

Portal vein thrombosis1 trial

Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02555111·112 enrolled

Deep Vein Thrombosis1 trial

Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)

Completed· Bayer logo

Bayer·Phase 2·NCT00839163·613 enrolled

Factor Xa Inhibitor1 trial

Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis

Completed· Bayer logo

Bayer·Phase 2·NCT00395772·543 enrolled

2 more indications

Orthopedic Surgeries1 trial

Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching

Unknown status·HHanoi Medical University··NCT03483181·4,000 enrolled

Fasting Conditions1 trial

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions

Unknown status·PPharmtechnology LLC·Phase 1·NCT04753489·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Xarelto. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xarelto compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xarelto. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Bayer

Xarelto

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rivaroxaban4 trials

Atrial Fibrillation3 trials

Portal vein thrombosis1 trial

Deep Vein Thrombosis1 trial

Factor Xa Inhibitor1 trial

Orthopedic Surgeries1 trial

Fasting Conditions1 trial

References

Drug Info

Quick Facts

Related News